Proteins are the biomolecules which have a vital role in the human beings. The biological activity of the proteins is based on the structures of the proteins. One of the structural importance of the proteins is making the proteins a validate drug targets. In the present article DHFR enzyme structure was predicted and validated. Further the experiment proceeds by performing the docking studies of this modeled structure with Breast cancer inhibitors giving a scope for one drug many cancer concept. The docking results were very promising with the H-bond interactions between Gly118, Gly21, Lys 56, Thr 147 and Asp 22.
INTRODUCTION
In the present day the designing of the drugs has gained attention and attracted many researchers in the pharmaceutical research 1 . In this process the structure of the protein plays a key role 2 . Not only in this specifically, the protein structures at large determines the functions of the proteins 3 . It is the amino acid sequences which determine the structure of the protein 4 . The relationship between the similar structures and the identical structures during the evolution were first identified by Chothia and Lesk 5 in the year 1986 and later by Sander and Schneider in 1999 6 . Hence, the proteins with dissimilar structure perform the similar function 7 and the proteins with the same structures perform different functions 8 . For the protein whose structures are not available the homology modelling is an ideal method to predict its structure 9 . This is accomplished with the structure of the known proteins as templates, knowing by the fact that similar sequences adopt similar folds 10 . Homology modelling has reportedly by exhibits a host of applications 11 . There are several reports in which the 3 D structures of the proteins are used to design new drugs [11] [12] [13] . The objective of the present investigation is to predict the protein structure of Dihydrofolate reductase DHFR and to dock it with the breast cancer inhibitors. The experiment aims at achieving the common drug for cancers. The enzyme dihydrofolate reductase catalyzes the reduction of NADPH to 5, 6, 7, 8-tetra hydrofolate 14 . DHFR is a very important enzyme in the biosynthesis of purines and amino acids of the cells and makes it an Antifolate drug target 15 . It works as an anticancer drug and is the first enzyme to be known as an chemotherapeutic agent. The drug acts by blocking the action of this enzyme.
MATERIALS AND METHODS Protein Selection
The protein for the present study was selected from Swissprot database which contains the details of the protein along with their sequences. Q86XFO, with the generic name Dihydrofolate reductase mitochondrial of the Homo sapiens was selected. The chain length is 187 residues.
Identification of the Template
The template identification was done by using BLAST (Protein-Protein blast) algorithm from Protein Data Bank.
Selection of the Template Chain
From the blast results, the template chain was selected on SPDBV. The FASTA sequence and the current layer are to be saved.
Alignment
The alignment of the sequence, both the target and the template was performed on CLUSTAL X.
Generation of the Structure and Validation
A Python based Modeller software was used to predict the python structure. The generated structure was validated by RAMPAGE and SAVS after the active site identification on Cast P.
Docking
The protein generated was then validated for its ability as a drug target. Molegro was used for docking the protein with the inhibitors. In the present experiment the inhibitors used are the Breast cancer inhibitors 16 giving a scope for one drug for multiple cancers.
RESULTS

Template identification
From the protein selected from the uniprot database, the template was identified upon the performance of BLAST. Based on the E-Value and identity (93 %) the protein with the accession no. 1MVS whose resolution is 1.90 and Rvalue, 0.186 was chosen. The results showed chain "A" to be identical.
Selection of the Chain From Template And Alignment
Using the SPDBV, the "A" chain was selected deleting the remaining chains and was saved. The target and the template were aligned and were saved in pir and DND file formats.
Generation of the Structure
Using the Modellar software the protein structure was generated. (Figure 1 & 2) The validation of the structure was done on RAMPAGE 17 and SAVS 18 which analysis the structure depending on the Ramachandran plot. (Figure 3) Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms and R-factor no greater than 20 %, a good quality model would be expected to have over 90 % in the most favoured regions.
Evaluation of residues
Active Site Identification
Identification of the active sites was done using the online software Cast P 19 which also talks about the residues present in the active sites. (Figure 5 
